Endocrine-Related Cancer, ISSN 1351-0088, 02/2014, Volume 21, Issue 1, pp. 1 - 16
Lung neuroendocrine tumors are catalogued in four categories by the World Health Organization (WHO 2004) classification. Its reproducibility and prognostic...
PROGNOSTIC STRATIFICATION | SURVIVAL | INTEROBSERVER VARIABILITY | NEOPLASMS | ONCOLOGY | IMAGE-ANALYSIS | ENDOCRINOLOGY & METABOLISM | SMALL-CELL CARCINOMA | ENDOCRINE TUMORS | CLASSIFICATION | PROLIFERATIVE INDEX | SPECTRUM | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Young Adult | Neoplasm Grading | Aged, 80 and over | Adult | Female | Retrospective Studies | Child | Carcinoma, Neuroendocrine - mortality | World Health Organization | Cross-Sectional Studies | Biomarkers, Tumor - analysis | Carcinoma, Neuroendocrine - classification | Kaplan-Meier Estimate | Proportional Hazards Models | Evidence-Based Medicine | Lung Neoplasms - classification | Ki-67 Antigen - analysis | Carcinoma, Neuroendocrine - pathology | Adolescent | Italy - epidemiology | Aged | Longitudinal Studies | Cohort Studies
PROGNOSTIC STRATIFICATION | SURVIVAL | INTEROBSERVER VARIABILITY | NEOPLASMS | ONCOLOGY | IMAGE-ANALYSIS | ENDOCRINOLOGY & METABOLISM | SMALL-CELL CARCINOMA | ENDOCRINE TUMORS | CLASSIFICATION | PROLIFERATIVE INDEX | SPECTRUM | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Young Adult | Neoplasm Grading | Aged, 80 and over | Adult | Female | Retrospective Studies | Child | Carcinoma, Neuroendocrine - mortality | World Health Organization | Cross-Sectional Studies | Biomarkers, Tumor - analysis | Carcinoma, Neuroendocrine - classification | Kaplan-Meier Estimate | Proportional Hazards Models | Evidence-Based Medicine | Lung Neoplasms - classification | Ki-67 Antigen - analysis | Carcinoma, Neuroendocrine - pathology | Adolescent | Italy - epidemiology | Aged | Longitudinal Studies | Cohort Studies
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_5
Abstract Background Highly myelosuppressive chemotherapy (HMC) is the standard treatment for several types of sarcoma. Severe neutropenia is a common adverse...
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2011, Volume 17, Issue 7, pp. 1964 - 1972
Purpose: NGR-hTNF exploits the tumor-homing peptide asparagine-glycine-arginine (NGR) for selectively targeting TNF-alpha to an aminopeptidase N overexpressed...
TRIAL | INTERFERON-GAMMA | ONCOLOGY | DRUGS | CONTINUOUS INFUSION | NECROSIS-FACTOR-ALPHA | ISOLATED LIMB PERFUSION | CANCER | MELPHALAN | MOTIF | GEMCITABINE | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Cisplatin - administration & dosage | Neoplasms - drug therapy | Disease-Free Survival | Receptors, Tumor Necrosis Factor - blood | Tumor Necrosis Factor-alpha - administration & dosage | Female | Aged | Neoplasms - pathology | Recombinant Fusion Proteins - administration & dosage
TRIAL | INTERFERON-GAMMA | ONCOLOGY | DRUGS | CONTINUOUS INFUSION | NECROSIS-FACTOR-ALPHA | ISOLATED LIMB PERFUSION | CANCER | MELPHALAN | MOTIF | GEMCITABINE | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Cisplatin - administration & dosage | Neoplasms - drug therapy | Disease-Free Survival | Receptors, Tumor Necrosis Factor - blood | Tumor Necrosis Factor-alpha - administration & dosage | Female | Aged | Neoplasms - pathology | Recombinant Fusion Proteins - administration & dosage
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 09/2010, Volume 182, Issue 5, pp. 720 - 721
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 10/2015, Volume 10, Issue 10, pp. 1437 - 1443
The potential to accurately quantify epidermal growth factor receptor ( ) mutations in plasma from non–small-cell lung cancer patients would enable more rapid...
Plasma | EGFR mutations | Next-generation sequencing | NSCLC | Predictive medicine | CELL LUNG-CANCER | GEFITINIB | ONCOLOGY | RESPIRATORY SYSTEM | FREE DNA | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Genetic Testing | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Treatment Outcome | Case-Control Studies | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Non-Small-Cell Lung - blood | Erlotinib Hydrochloride - therapeutic use | Lung Neoplasms - blood | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Clinical Trials, Phase II as Topic
Plasma | EGFR mutations | Next-generation sequencing | NSCLC | Predictive medicine | CELL LUNG-CANCER | GEFITINIB | ONCOLOGY | RESPIRATORY SYSTEM | FREE DNA | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Genetic Testing | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Treatment Outcome | Case-Control Studies | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Non-Small-Cell Lung - blood | Erlotinib Hydrochloride - therapeutic use | Lung Neoplasms - blood | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Clinical Trials, Phase II as Topic
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 2014, Volume 15, Issue 5, pp. 346 - 355
Micro-Abstract The management of patients with oligometastatic non–small-cell lung cancer (NSCLC) is controversial. The findings of this metaanalysis of 757...
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Metastectomy | SABR/SBRT | NSCLC | Radiotherapy | Oligometastases | PRIMARY TUMOR | SOLITARY BRAIN METASTASIS | FOLLOW-UP | ADRENAL METASTASIS | SURGICAL-TREATMENT | CHEMOTHERAPY | RADIATION-THERAPY | RADICAL TREATMENT | ONCOLOGY | STEREOTACTIC BODY RADIOTHERAPY | CARCINOMA | Carcinoma, Non-Small-Cell Lung - pathology | Adenocarcinoma - pathology | Prognosis | Humans | Proportional Hazards Models | Lung Neoplasms - pathology | Risk | Survival Rate | Lung Neoplasms - therapy | Disease-Free Survival | Carcinoma, Non-Small-Cell Lung - therapy | Neoplasm Metastasis | Adenocarcinoma - therapy
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Metastectomy | SABR/SBRT | NSCLC | Radiotherapy | Oligometastases | PRIMARY TUMOR | SOLITARY BRAIN METASTASIS | FOLLOW-UP | ADRENAL METASTASIS | SURGICAL-TREATMENT | CHEMOTHERAPY | RADIATION-THERAPY | RADICAL TREATMENT | ONCOLOGY | STEREOTACTIC BODY RADIOTHERAPY | CARCINOMA | Carcinoma, Non-Small-Cell Lung - pathology | Adenocarcinoma - pathology | Prognosis | Humans | Proportional Hazards Models | Lung Neoplasms - pathology | Risk | Survival Rate | Lung Neoplasms - therapy | Disease-Free Survival | Carcinoma, Non-Small-Cell Lung - therapy | Neoplasm Metastasis | Adenocarcinoma - therapy
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2011, Volume 29, Issue 15_suppl, pp. 7090 - 7090
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 15_suppl, pp. e19558 - e19558
Journal Article
Pharmacological Reviews, ISSN 0031-6997, 03/2003, Volume 55, Issue 1, pp. 57 - 103
In mammalian cells, the process of malignant transformation is characterized by the loss or down-regulation of tumor-suppressor genes and/or the mutation or...
WILD-TYPE P53 | CISPLATIN-BASED CHEMOTHERAPY | GLYCOPROTEIN-MEDIATED RESISTANCE | MICROSATELLITE INSTABILITY | THERAPY-ONCOLOGY-GROUP | PHARMACOLOGY & PHARMACY | MULTIDRUG-RESISTANCE PROTEIN | HER-2/NEU GENE-EXPRESSION | EPIDERMAL GROWTH-FACTOR | TOPOISOMERASE-I INHIBITORS | FACTOR RECEPTOR | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Drug Resistance, Neoplasm - genetics | Pharmacogenetics | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Treatment Outcome | Antineoplastic Agents - therapeutic use | Structure-Activity Relationship | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Agents - chemistry | Randomized Controlled Trials as Topic
WILD-TYPE P53 | CISPLATIN-BASED CHEMOTHERAPY | GLYCOPROTEIN-MEDIATED RESISTANCE | MICROSATELLITE INSTABILITY | THERAPY-ONCOLOGY-GROUP | PHARMACOLOGY & PHARMACY | MULTIDRUG-RESISTANCE PROTEIN | HER-2/NEU GENE-EXPRESSION | EPIDERMAL GROWTH-FACTOR | TOPOISOMERASE-I INHIBITORS | FACTOR RECEPTOR | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Drug Resistance, Neoplasm - genetics | Pharmacogenetics | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Treatment Outcome | Antineoplastic Agents - therapeutic use | Structure-Activity Relationship | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Agents - chemistry | Randomized Controlled Trials as Topic
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 10/2015, Volume 10, Issue 10, pp. 1458 - 1467
To assess the safety and immunogenicity of MAGE-A3 immunotherapeutic in patients with stage IB–III MAGE-A3-positive non–small-cell lung cancer (NSCLC) who were...
Immunostimulant | Adjuvant chemotherapy | Vaccine | Immunotherapy | MAGE-A3 | Non–small cell lung carcinoma | Non-small cell lung carcinoma | VINORELBINE | PHASE-III | VACCINATION | ANTIBODY | COMBINATION | IMMUNIZATION | THERAPY | CISPLATIN | ONCOLOGY | RESPIRATORY SYSTEM | DOUBLE-BLIND | Carcinoma, Non-Small-Cell Lung - pathology | Recombinant Proteins - therapeutic use | Lung Neoplasms - drug therapy | Immunotherapy - methods | Humans | Middle Aged | Neoplasm Proteins - therapeutic use | Lung Neoplasms - pathology | Male | Lung Neoplasms - therapy | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Carcinoma, Non-Small-Cell Lung - therapy | Vinblastine - analogs & derivatives | Antigens, Neoplasm - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Chemotherapy, Adjuvant | Neoplasm Staging | Cohort Studies | Life Sciences | Human health and pathology | Pulmonology and respiratory tract | Cancer
Immunostimulant | Adjuvant chemotherapy | Vaccine | Immunotherapy | MAGE-A3 | Non–small cell lung carcinoma | Non-small cell lung carcinoma | VINORELBINE | PHASE-III | VACCINATION | ANTIBODY | COMBINATION | IMMUNIZATION | THERAPY | CISPLATIN | ONCOLOGY | RESPIRATORY SYSTEM | DOUBLE-BLIND | Carcinoma, Non-Small-Cell Lung - pathology | Recombinant Proteins - therapeutic use | Lung Neoplasms - drug therapy | Immunotherapy - methods | Humans | Middle Aged | Neoplasm Proteins - therapeutic use | Lung Neoplasms - pathology | Male | Lung Neoplasms - therapy | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Carcinoma, Non-Small-Cell Lung - therapy | Vinblastine - analogs & derivatives | Antigens, Neoplasm - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Chemotherapy, Adjuvant | Neoplasm Staging | Cohort Studies | Life Sciences | Human health and pathology | Pulmonology and respiratory tract | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2008, Volume 26, Issue 15_suppl, pp. 20614 - 20614
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 15, pp. 2604 - 2611
Purpose NGR-hTNF consists of human tumor necrosis factor alpha (hTNF-alpha) fused to the tumor-homing peptide asparagine-glycine-arginine (NGR) able to...
PEMETREXED PLUS | TRIAL | SURVIVAL | INTERFERON-GAMMA | CISPLATIN | ONCOLOGY | CONTINUOUS INFUSION | PERFUSION | COMBINATION | CANCER | CHEMOTHERAPY | Mesothelioma - pathology | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Mesothelioma - drug therapy | Pleural Neoplasms - drug therapy | Disease-Free Survival | Tumor Necrosis Factor-alpha - therapeutic use | Tumor Necrosis Factor-alpha - adverse effects | Aged, 80 and over | Female | Aged | Pleural Neoplasms - pathology | Cohort Studies | Index Medicus
PEMETREXED PLUS | TRIAL | SURVIVAL | INTERFERON-GAMMA | CISPLATIN | ONCOLOGY | CONTINUOUS INFUSION | PERFUSION | COMBINATION | CANCER | CHEMOTHERAPY | Mesothelioma - pathology | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Mesothelioma - drug therapy | Pleural Neoplasms - drug therapy | Disease-Free Survival | Tumor Necrosis Factor-alpha - therapeutic use | Tumor Necrosis Factor-alpha - adverse effects | Aged, 80 and over | Female | Aged | Pleural Neoplasms - pathology | Cohort Studies | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2012, Volume 23, Issue suppl 11, pp. xi43 - xi44
Journal Article